This is Life Sciences. Powered by AI.

Harness the power of AI to accelerate patient access to therapy—enabling care teams to deliver the right care to the right patients at the right time.

Biopharma companies are harnessing the power of AI

Accelerate access to care and prevent drop out

Artificial intelligence is changing how healthcare is being delivered—biopharma and medtech companies are adapting their go-to-market strategy for therapies to reach more patients who need them—when they need them.

AI, coupled with novel clinical workflow tools, is enabling healthcare providers to detect disease earlier, unite patients with specialists, improve outcomes, and prevent patient leakage—all in real time and from the palm of their hands. AI is revolutionizing healthcare—biopharma and medtech companies are changing, are you?

Viz.ai is being used today in over 1,400+ hospitals and at top integrated delivery networks (IDNs) in the United States and serves one patient every 14 seconds. We empower >35,000 clinicians and healthcare providers to detect diseases earlier, address barriers in the patient journey, and get patients to the treatments they need to optimize outcomes—backed by real-world evidence in over 100 clinical publications.

Improve outcomes in more patients

3x

increase in patients to specialist

Expand market development

Expand patient access to your treatments.

Learn more

50%

up to

of follow-ups are not completed

Care pathways

Close gaps in patient care by minimizing the number of patients getting lost in the system.

increase trial enrollment rates by

3x

Accelerate trial enrollment

Increase clinical trial enrollment with efficient identification and recruitment capabilities.

Learn more

How point-of-care AI could transform commercial strategy while improving patient outcomes

Get ready, pharma! Download the guide for 4 use cases that challenge everything you thought possible

Download the whitepaper

Biopharma Case Study

In August 2023, Viz.ai received De Novo approval by the FDA for an artificial intelligence (AI) detection algorithm designed to detect hypertrophic cardiomyopathy (HCM), creating a new regulatory category for cardiovascular machine learning-based notification software. The deployment of this algorithm was made possible through financial support from Bristol Myers Squibb.

The Viz HCM algorithm uses AI to analyze ECGs and flag any patterns that suggest HCM. It ingests 12-lead ECG recordings, and the analyzed results are made available on Viz’ mobile ECG viewer, facilitating communication and image sharing with the entire cardiac care team to expedite patient triage for additional diagnostic workup.

Viz HCM is one of twelve FDA-cleared AI algorithms on the enterprise-wide, clinically validated Viz.ai platform, which has been demonstrated to increase access to treatment and improve patient outcomes.

Start a conversation

Biopharma

Tom Krohn

tom.krohn@viz.ai

Biotech & Medtech

Bill Stadlander

bill.stadtlander@viz.ai

The Viz.ai Advantage

Trusted by

1500+

hospitals with users across many specialties and disease areas

Screening 1 patient every

12

seconds

>90%

of alerts viewed within 5 minutes

Backed by robust clinical evidence with

100+

publications and abstracts